Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10915845 | Nuclear Medicine and Biology | 2016 | 8 Pages |
Abstract
The clinical interest in validation of 68Galabeled agents has increased in the past years due to availability of generators from different vendors (Eckert-Ziegler, ITG, iThemba), favorable approach of U.S. FDA agency to initiate clinical trials, and collaboration of U.S. centers with leading EU clinical sites. The list of 68Ga-labeled tracers evaluated in clinical studies should growth because of the sensitivity of PET technique, the simplicity of the shakebake approach for the dose preparation and reliability of 68Ge/68Ga generators. Our studies have confirmed the reproducible elution profile, and high reliability of ITG GmbH generators required for routine doses preparation according to FDA recommendations.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Izabela Tworowska, David Ranganathan, Sanjay Thamake, Ebrahim Delpassand, Alireza Mojtahedi, Michael K. Schultz, Konstantin Zhernosekov, Sebastian Marx,